NervGen Pharma

NervGen Pharma EBIT per Share

The EBIT per Share of NervGen Pharma (NGEN.V) as of Oct 18, 2026 is -0.35 CAD. In the previous year, EBIT per Share was -0.37 CAD — a change of -6.31% (higher).

EBIT per Share

-0.35CAD

YoY

-6.31%

Last updated:

EBIT per Share of NervGen Pharma is 2025 -0.35 CAD. EBIT per Share of NervGen Pharma was 2024 -0.37 CAD. It decreases by -6.31% higher compared to the previous year.

The NervGen Pharma EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-0.30 CAD
Jan 1, 2024
-0.37 CAD
Jan 1, 2025
-0.35 CAD
Jan 1, 2026 (e)
0.00 CAD
Jan 1, 2027 (e)
0.00 CAD
Jan 1, 2028 (e)
0.00 CAD
Jan 1, 2029 (e)
6.47 CAD
Jan 1, 2030 (e)
9.69 CAD
The NervGen Pharma EBIT per Share history
YEAREBIT per ShareYoY
est9.69CAD+49.77%
est6.47CAD—
est0.00CAD—
est0.00CAD—
est0.00CAD-100.00%
-0.35CAD-6.31%
-0.37CAD+23.69%
-0.30CAD-22.94%
-0.39CAD+39.05%
-0.28CAD-11.75%
-0.32CAD-8.10%
-0.34CAD+391.04%
-0.07CAD+15,814.30%
-0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

NervGen Pharma Stock analysis

What does NervGen Pharma do? NervGen Pharma Corp, based in Vancouver, Canada, operates in the Health Care sector as a regenerative medicine company. It focuses on discovering, developing, and commercializing therapeutics for nerve damage, including spinal cord and peripheral nerve injuries. The company is advancing its lead compound NVG-291 for spinal cord injury, Alzheimer’s disease, and multiple sclerosis. With 10 full-time employees, it has two wholly owned subsidiaries, NervGen US Inc. and NervGen Australia Pty Ltd. NervGen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NervGen Pharma stock

EBIT per Share of NervGen Pharma is -0.35 CAD in 2025.

EBIT per Share of NervGen Pharma changed from -0.37 CAD to -0.35 CAD, representing a -6.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share NervGen Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — NervGen Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — NervGen Pharma